SCHEMBL1169744

SCHEMBL1169744

COC(=O)c1ccc(CNS(=O)(=O)c2ccc(Cl)cc2)cc1F

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.54
MAPK1 P28482 2/20 0.50
ALDH1A1 P00352 1/20 0.50
HSD17B10 Q99714 1/20 0.50
KDM4E B2RXH2 2/20 0.49
POLB P06746 2/20 0.46
FLT1 P17948 1/20 0.46
FLT4 P35916 1/20 0.46
KDR P35968 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TP53 P04637 2/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
TUBB P07437 1/20 0.46
CNR2 P34972 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1169813 0.86 CYP19A1 (0.60) CYP19A1MAPK1KDM4EPOLBSMN1; SMN2
SCHEMBL1169693 0.85 LMNA (0.54) CYP19A1MAPK1ALDH1A1KDM4EPOLB
SCHEMBL119269 0.81 SMN1; SMN2 (0.64) MAPK1ALDH1A1KDM4EPOLBSMN1; SMN2
SCHEMBL1169525 0.80 POLB (0.65) CYP19A1MAPK1ALDH1A1HSD17B10KDM4E
SCHEMBL18422643 0.76 F2 (0.47) ALDH1A1KDM4EPOLBSMN1; SMN2KMT2A
SCHEMBL1350185 0.74 ABL1 (0.64) ALDH1A1KDM4EPOLBFLT1FLT4
SCHEMBL27457377 0.74 ALDH1A1 (0.50) CYP19A1MAPK1ALDH1A1MEN1KMT2A
SCHEMBL1169969 0.73 CXCR3 (0.80) SMN1; SMN2TP53MEN1KMT2A
SCHEMBL10205766 0.73 CYP19A1 (0.72) CYP19A1MAPK1ALDH1A1HSD17B10SMN1; SMN2
SCHEMBL16469772 0.73 ALDH1A1 (0.47) MAPK1ALDH1A1HSD17B10KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110028509-A1 Sulfonamides MERCK SERONO SA (CH) 2011-02-03 US disclosed
US-20110028509-A1 Sulfonamides MERCK SERONO SA (CH) 2011-02-03 US disclosed
US-20110028509-A1 Sulfonamides MERCK SERONO SA (CH) 2011-02-03 US disclosed
EP-2265575-A2 SULFONAMIDES Merck Serono S.A. (CH) 2010-12-29 EP disclosed
WO-2009124962-A2 SULFONAMIDES MERCK SERONO S.A. (CH) 2009-10-15 WO disclosed
WO-2009124962-A2 SULFONAMIDES MERCK SERONO S.A. (CH) 2009-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028509-A1 Sulfonamides CXCR3, CXCR2, CXCR1 CYP19A1 1874/4885MAPK1 3923/4885ALDH1A1 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.